Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics

October 09, 2023 10:04 AM PDT | By Invezz

Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics — Image source: Invezz

Bristol-Myers will get to expand its footprint in oncology

The all-cash transaction values each share of the oncology therapies company at $58 – close to 4.0% below their previous close.

Bristol-Myers will add Krazati – an FDA approved treatment for a type of lung cancer to its portfolio with this acquisition. Chris Boerner – its Chief Executive-Elect said in a press release today:

Mirati is another step forward in our efforts to grow our diversified oncology portfolio and further strengthen Bristol Myers’ pipeline for the latter half of the decade and beyond.

The pharmaceutical behemoth expects to close this deal next year in the first half, provided that it satisfied customary closing conditions, including shareholders’ approval.

JUST IN: Major drug companies including Johnson & Johnson, Merck and Bristol Myers Squibb have committed to participating in Medicare drug price negotiations with the federal government, the White House says. https://t.co/B4KU3UjSDY
— NBC News (@NBCNews) October 3, 2023

Bristol-Mirati deal may eventually be valued at $70 a share

Bristol-Myers expects this merger with the biotech firm to dilute its adjusted per-share earnings by 35 cents in the first year after completing the transaction.

The multinational is scheduled to report its Q3 results in the final week of October. Consensus is for it to earn $1.79 a share this quarter versus $1.99 per share a year ago.

The definitive agreement announced this morning also offers one Contingent Value Right (non-tradeable) for each share of Mirati Therapeutics “potentially worth $12 per share in cash”, as per the press release.

Bristol-Myers had also bought Turning Point Therapeutics – another cancer biotech company last year for a total cash consideration of $4.1 billion.

Watch here: https://www.youtube.com/embed/HOP5DD7KPh4?feature=oembed

The post Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics appeared first on Invezz.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.